Literature DB >> 21421316

Assessing upper limb function in nonambulant SMA patients: development of a new module.

Elena Mazzone1, Flaviana Bianco, Diego Martinelli, Allan M Glanzman, Sonia Messina, Roberto De Sanctis, Marion Main, Michelle Eagle, Julaine Florence, Kristin Krosschell, Gessica Vasco, Marco Pelliccioni, Marilena Lombardo, Marika Pane, Richard Finkel, Francesco Muntoni, Enrico Bertini, Eugenio Mercuri.   

Abstract

We report the development of a module specifically designed for assessing upper limb function in nonambulant SMA patients, including young children and those with severe contractures. The application of the module to a preschool cohort of 40 children (age 30-48 months) showed that all the items could be completed by 30 months. The module was also used in 45 nonambulant SMA patients (age 30 months to 27 years). Their scores were more variable than in the preschool cohort, ranging from 0 to 18. The magnitude of scores was not related to age (r=-0.19). The upper limb scores had a good correlation with the Hammersmith Functional Motor Scale, r=0.75, but the upper limb function did not always strictly follow the overall gross motor function. These findings suggest that even some of the very weak nonambulant children possess upper limb skills that can be measured.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21421316     DOI: 10.1016/j.nmd.2011.02.014

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  18 in total

1.  Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.

Authors:  Suzan M Hammond; Gareth Hazell; Fazel Shabanpoor; Amer F Saleh; Melissa Bowerman; James N Sleigh; Katharina E Meijboom; Haiyan Zhou; Francesco Muntoni; Kevin Talbot; Michael J Gait; Matthew J A Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205

2.  Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.

Authors:  Kristin J Krosschell; Michael Bosch; Leslie Nelson; Tina Duong; Linda P Lowes; Lindsay N Alfano; Danielle Benjamin; Terri B Carry; Ginger Devine; Carolyn Kelley; Rebecca Gadekan; Elizabeth C Malkus; Amy Pasternak; Stephanie Provance-Orr; Lynne Roemeiser-Logan; Alina Nicorici; Donata Trussell; Sally Dunaway Young; Jennifer R Fetterman; Jacqueline Montes; Penny J Powers; Rebecca Quinones; Janet Quigley; Christopher S Coffey; Jon W Yankey; Amy Bartlett; John T Kissel; Stephen J Kolb
Journal:  J Neuromuscul Dis       Date:  2018

3.  Different trajectories in upper limb and gross motor function in spinal muscular atrophy.

Authors:  Giorgia Coratti; Maria Carmela Pera; Jacqueline Montes; Amy Pasternak; Mariacristina Scoto; Giovanni Baranello; Sonia Messina; Sally Dunaway Young; Allan M Glanzman; Tina Duong; Roberto De Sanctis; Elena Stacy Mazzone; Evelin Milev; Annemarie Rohwer; Matthew Civitello; Marika Pane; Laura Antonaci; Anna Lia Frongia; Maria Sframeli; Gian Luca Vita; Adele DʼAmico; Irene Mizzoni; Emilio Albamonte; Basil T Darras; Enrico Bertini; Valeria A Sansone; Francesca Bovis; John Day; Claudio Bruno; Francesco Muntoni; Darryl C De Vivo; Richard Finkel; Eugenio Mercuri
Journal:  Muscle Nerve       Date:  2021-08-09       Impact factor: 3.852

4.  Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial.

Authors:  Andreea Mihaela Seferian; Amélie Moraux; Aurélie Canal; Valérie Decostre; Oumar Diebate; Anne Gaëlle Le Moing; Teresa Gidaro; Nicolas Deconinck; Frauke Van Parys; Wendy Vereecke; Sylvia Wittevrongel; Mélanie Annoussamy; Michèle Mayer; Kim Maincent; Jean-Marie Cuisset; Vincent Tiffreau; Severine Denis; Virginie Jousten; Susana Quijano-Roy; Thomas Voit; Jean-Yves Hogrel; Laurent Servais
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

5.  Spontaneous Breathing Pattern as Respiratory Functional Outcome in Children with Spinal Muscular Atrophy (SMA).

Authors:  A LoMauro; A Aliverti; C Mastella; M T Arnoldi; P Banfi; G Baranello
Journal:  PLoS One       Date:  2016-11-07       Impact factor: 3.240

6.  Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.

Authors:  Xing Chen; Juliane Siebourg-Polster; Detlef Wolf; Christian Czech; Ulrike Bonati; Dirk Fischer; Omar Khwaja; Martin Strahm
Journal:  PLoS One       Date:  2017-01-25       Impact factor: 3.240

7.  A qualitative study of perceptions of meaningful change in spinal muscular atrophy.

Authors:  Sarah McGraw; Ying Qian; Jeff Henne; Jill Jarecki; Kenneth Hobby; Wei-Shi Yeh
Journal:  BMC Neurol       Date:  2017-04-04       Impact factor: 2.474

8.  International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy: Rome, 15-16 February 2012.

Authors:  Eugenio Mercuri; Craig McDonald; Anna Mayhew; Julaine Florence; Elena Mazzone; Flaviana Bianco; Valerie Decostre; Laurent Servais; Valeria Ricotti; Nathalie Goemans; Elizabeth Vroom
Journal:  Neuromuscul Disord       Date:  2012-07-13       Impact factor: 4.296

9.  Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial.

Authors:  Andreea Mihaela Seferian; Amélie Moraux; Mélanie Annoussamy; Aurélie Canal; Valérie Decostre; Oumar Diebate; Anne-Gaëlle Le Moing; Teresa Gidaro; Nicolas Deconinck; Frauke Van Parys; Wendy Vereecke; Sylvia Wittevrongel; Michèle Mayer; Kim Maincent; Isabelle Desguerre; Christine Thémar-Noël; Jean-Marie Cuisset; Vincent Tiffreau; Severine Denis; Virginie Jousten; Susana Quijano-Roy; Thomas Voit; Jean-Yves Hogrel; Laurent Servais
Journal:  PLoS One       Date:  2015-02-02       Impact factor: 3.240

10.  A continuous repetitive task to detect fatigability in spinal muscular atrophy.

Authors:  Marloes Stam; Renske I Wadman; Bart Bartels; Maureen Leeuw; Henk-Jan Westeneng; Camiel A Wijngaarde; Leonard H van den Berg; W Ludo van der Pol
Journal:  Orphanet J Rare Dis       Date:  2018-09-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.